





 Background/Objective: Dual-eligible Medicare-Medicaid beneficiaries account for a disproportionate average cost per person for both Medicare and Medicaid – twice the cost compared to any other Medical Assistance recipients. In Pennsylvania, there are over 350,000 dual-eligible beneficiaries. Pennsylvania enacted Act 92 in 2016, creating set fees for observation services in acute care hospitals, aimed at controlling hospitalization costs. The overall objective of this study was to examine the effect of Act 92 on hospitalization costs of dual Medicare-Medicaid beneficiaries.
Methods: The study population consisted of beneficiaries who reported to the hospital with a claims data diagnosis code of ‘chronic obstructive pulmonary disease and bronchiectasis’ or ‘nonspecific chest pain’ between July 1, 2015-January 28, 2016 (prior to Act 92) and between July 1, 2016-January 28, 2017 (after Act 92). Linear regression models assessed the significance of the association between time period and index hospitalization costs, and logistic regression models were used to evaluate the association of time period with the probability of inpatient admission.
Results: Non-parametric Wilcoxon test had a significant difference in mean index cost between beneficiaries hospitalized prior to Act 92 compared to after Act 92 (p<0.0001). Generalized linear regression model results showed reporting to the hospital prior to Act 92 compared to after did not have a statistically significant association with cost of hospitalization (β=255.09, p=0.2003) when adjusting for covariates. After adjusting for covariates, a logistic regression model showed reporting to the hospital after Act 92 was associated with a statistically significant reduction in inpatient admission (OR=0.672, P=0.0472). 
Conclusion: Act 92 had no direct impact on total cost of an index hospitalization, but reporting to the hospital after the enactment of Act 92 was associated with a statistically significant decrease in the likelihood of being admitted as an inpatient compared to before Act 92. This topic is worth further studies with larger populations, more diagnosis codes, and longer follow-up times for readmission. The public health significance of Act 92 is reduced spending for health insurance companies, which can trickle-down to reduce burdensome healthcare costs for observation hospital stays for special needs population of beneficiaries. 
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Pennsylvania passed Act 92 in December 2015 in response to the rising financial burden of beneficiaries to government provided health insurance. This introduction will describe Act 92 and the implications of this legislation before describing the population affected by the Act. Other pieces of legislation enacted around the same time, and two diagnosis codes that could be affected by Act 92 are then examined, followed by a description of the population source for this study. The objectives of this analysis are to measure the effect of Act 92 on 1) total cost of hospitalization paid by the Insurer, 2) probability of 30-day readmissions, and 3) total cost of readmission hospitalizations paid by the Insurer. 
1.1	P.L. 500, No. 92 (Act 92)
“Section 6. Section 443.3(a) of the act is amended by adding a paragraph to read:
Section 443.3. Other Medical Assistance Payments. - - (a) Payments on behalf of eligible persons shall be made for other services, as follows:
* * *
(1.1) Rates established by the department for observation services provided by or furnished under the direction of a physician and furnished by a hospital. Payment for observation services shall be made in an amount specified by the department by notice in the Pennsylvania Bulletin and shall be effective for date of service on or after July 1, 2016. Payment for observation services shall be subject to conditions specified in the department’s regulations, including regulations adopted by the department to implement this paragraph. Pending adoption of regulations implementing this paragraph, the conditions for payment of observation services shall be specified in a medical assistance bulletin.” [1]
1.2	What is Act 92?
Act 92, a Pennsylvania state law, was the 92nd law passed by the 500th state legislature on December 28, 2015 [1]. The act established a series of amendments to the Public Welfare Code of 1967 (P.L. 31, No. 21), one amendment being the creation of set rates for observation services received by beneficiaries of Medicaid. Medicaid is a government health insurance run by state or local governments with federal oversights. Medicaid is overseen by the Centers for Medicare & Medicaid Services (CMS), which also manages Medicare on a federal level. Medicaid mainly serves low-income individuals and also serves uninsured children and individuals who are blind or disabled. The aim of Act 92 was to reduce costs associated with extended periods of time spent in an acute care facility where the treating physician is not sure whether to admit the patient as an inpatient or treat the patient through an outpatient setting through the creation of observation services.  Act 92 stated that the effects of the new payment system for observation services would go into effect on July 1, 2016 [1].
1.3	What did Act 92 amend?
Prior to the enactment of Act 92, there were no set fees or billing codes related directly to observation services in Pennsylvania [2]. A beneficiary of Medicaid or Medicare who reported to the hospital would either be admitted as an inpatient or treated as an outpatient, each having a different structure for the fiscal responsibility of the payment. For Medicaid in 2013, both inpatient and outpatient hospital services are designated as mandatory benefits [3]. Individual payments for Medicaid vary by income with those whose family income is 100% of the federal poverty line (FPL) or less having a copayment of $75 for inpatient admission with varying copayments for families with a greater income [4].
Act 92 allowed for the Pennsylvania Department of Human Services (PA DHS) to execute this section of the law, creating a set of fees for observation services for Medicaid beneficiaries (Table 10, Appendix)[1]. The observation fees created are based on the beneficiary’s disease severity and time spent with the beneficiary, and the fees are on a per day basis and cover all services received under observation [2], exclusive of any blood and blood products received [5]. The estimated fiscal impact of this section of Act 92 for the 2016-2017 fiscal year was $28.28 million for implementation, of which $10.229 million comes from state general funds [2].
1.4	What is Observation versus Inpatient Admission?
The enactment of Act 92 required the PA DHS to clearly define observation services when they developed observation payments. Observation services were defined as a stay in the hospital meant for a physician to have enough time to observe a Medicaid beneficiary to decide whether an inpatient admission is warranted or whether discharge is appropriate [2]. While the legislation was meant to impact Medicaid beneficiaries, the current study was conducted with a population of dual-eligible Medicare-Medicaid beneficiaries, which the legislation was also applied to, in order to address sample size concerns from the source data. Act 92 also will impact dual-eligible Medicare-Medicaid beneficiaries, but the impact may not be as strong, as Medicare is the primary payer for this population. 
When creating the guidelines to effectively enact Act 92 in the state of Pennsylvania, the PA DHS created three main components that must be met for a patient visit to an acute care hospital to be considered observation: 1) services received are medically necessary, 2) services are received in an outpatient setting, and 3) services must last eight or more hours. For observation services to meet the requirement of being medically necessary, there must be written orders for observation services in the patient’s chart by a physician with admitting privileges [5]. The time frame for observation services begins once the orders are written in a patient’s medical records, and continues until the beneficiary is admitted as an inpatient or the last medical service is received and the beneficiary is discharged. The time a Medicaid beneficiary spends in the hospital after the last service is received and formal discharge do not count towards the eight-hour minimum for observation services. Recovery time spent in a hospital after an outpatient procedure also does not count towards observation services. There is no maximum time limit set for the duration of observation services [5], but it is recommended they do not exceed 48 hours in length. Inpatient admission also requires a doctor’s written request, and is aimed to admit an individual to a hospital with the expectation the individual would spend two or more days.  
1.5	Dual-eligible Medicare-Medicaid Beneficiaries
Dual-eligible Medicare-Medicaid beneficiaries are individuals who receive Medicare and Medicaid. Medicare, which mainly serves individuals over the age of 65, is the primary payer for dual-eligible Medicare-Medicaid beneficiaries. Part A of Medicare is responsible for inpatient hospital stays and Part B is responsible for any services that are received while being treated as an outpatient [6]. Any services covered under Part B result in the beneficiary being fiscally responsible for 20% of all services received until the total of the Part A deductible is matched [7]. 
Special needs plans (SNPs) were created by the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003 to assist certain parts of the Medicare population that required more specialized and individualized healthcare through managed care organizations (MCOs). There are three types of populations that qualify for a SNP: dual eligible Medicare and Medicaid beneficiaries, beneficiaries with certain chronic diseases, and beneficiaries who are institutionalized for health care reasons. As of 2011, there were an estimated 1.3 million beneficiaries of SNPs, which accounted for 3% of the Medicare population, a majority of which (~80%) are enrolled in a dual-eligible Medicare-Medicaid special needs plan (D-SNP) [8]. This study focuses solely on the effects of Act 92 on D-SNP enrollees.  
In the past decade, D-SNP enrollment and plan availability have increased from 670,499 enrollees (74% of all SNP enrollees) in May 2007 to 1,976,997 enrollees in May 2017 (83% of all enrollees) [9] and from 321 plans to 377 plans, peaking in 2008 with 440 D-SNP plans [9]. It is important to note that not all dual beneficiaries have a qualifying D-SNP plan to enroll in, and Medicare is the primary payer for any individual who is a full-dual eligible beneficiary. 
Dual-eligible enrollees are a unique population as they account for a disproportionate cost for both Medicare and Medicaid. According to the January 2017 MedPAC and MACPAC Data Book: Beneficiaries Dually Eligible for Medicare and Medicaid, published jointly by the Medicare Payment Advisory Commission (MedPAC) and the Medicaid and CHIP Payment and Access Commission (MACPAC), in 2012 dual-eligible beneficiaries accounted for 20% of the Medicare population, but 34% of Medicare spending. The same individuals made up 15% of the Medicaid population, yet accounted for 33% of Medicaid spending during the same year. 
On a per beneficiary level, dual-eligible beneficiaries have an average cost that is over double the next most costly beneficiary group. Full dual-eligible beneficiaries cost $33,400 on average per beneficiary, while partial dual-eligible Medicare-Medicaid beneficiaries cost $15,700 on average. Non-dual, aged, blind, or disabled Medicaid only beneficiaries cost an average of $15,500, and non-dual eligible Medicare beneficiaries cost $8,200 [10].
In Pennsylvania, the trends of dual-eligible beneficiaries tend to follow national trends. In 2012, the state population was 12.766 million individuals, of which about 3.5% of the population (450,000 individuals) were eligible to receive benefits from Medicare and Medicaid. Of those 450,000 individuals, 369,000 (82%) were full-dual eligible beneficiaries [11]. 
1.6	Other Legislation taking Place during the time of Act 92
It is important to be cognizant of the political landscape that was occurring as Act 92 was enacted. Other pieces of legislation taking effect around the same time have the potential to confound any associations of Act 92 with lower costs or the use of observation services. As this study is completed with a dual-eligible Medicare-Medicaid population, there is the potential for federal laws affecting Medicare beneficiaries to have an impact on the associations being evaluated.  
1.6.1	Medicare Accountable Care Organization Implementation
In response to the section in the Affordable Care Act, which intended to eliminate unnecessary healthcare spending in an effort to reduce the deficit, accountable care organizations (ACOs) were created. An ACO is a network of hospitals, doctors, and other healthcare professionals that work together to coordinate and provide more individualized care for Medicare beneficiaries [12, 13].  ACOs were established on January 1, 2012 and were initially predicted to save Medicare up to $930 million over a three-year period [13]. Between their creation and 2015, 744 organizations became an ACO, serving approximately six million Medicare beneficiaries [12].
A cohort study evaluated the impact ACOs had on over 15 million Medicare beneficiaries using claims data from 2009-2013. The study also evaluated a sub-cohort of more vulnerable beneficiaries defined as “all Medicare beneficiaries 66 years or older who had at least 3 Hierarchical Condition Categories (HCCs)”, 31% of which had chronic obstructive pulmonary disease  ADDIN EN.CITE [14].  This study found statistically significant decreases of $34 per beneficiary-quarter spending, 1.3 hospitalizations per 1,000 beneficiary-quarters, and 3.0 emergency department visits per 1,000 beneficiary-quarters among the whole study population (decreases in $114 per beneficiary-quarter spending, 2.9 hospitalizations per 1,000 beneficiary-quarters, and 4.1 emergency department visits per 1,000 beneficiary-quarters for the clinically vulnerable population) for beneficiaries who were a part of an ACO contract compared to beneficiaries who were not  ADDIN EN.CITE [14]. Overall the clinically vulnerable population was costlier than the overall population ($22,235 per person compared to $10,378 per person), with 36% of the cost due to acute care – the largest component of overall spending  ADDIN EN.CITE [14]. On an overall level, ACOs were associated with a 1.3% reduction in hospital spending  ADDIN EN.CITE [14].
Since their creation, ACOs have been constantly evolving. In 2016, the Next Generation ACO program started, which enrolled existing ACOs in a program to start the transformation of healthcare in the United States from a focus on quantity-of-care to quality-of-care [15]. In addition, enrollment has started for organizations to establish Medicare-Medicaid accountable care organizations (MMACOs) to expand the reach of ACOs to also target Medicaid beneficiaries. Start dates for these enrollments are in 2018, 2019, and 2020 [15]. 
1.6.2	Centers for Medicare & Medicaid 2-Midnight Rule
In 2013, CMS developed and announced their 2-midnight rule during the same time a report from the United States Department of Health and Human Services’ Office of Inspector General was published documenting inappropriate lengths of stay in acute care facilities. The report concluded the number of improperly long observation stays (greater than 24 hours in length) and inappropriately short inpatient stays (an admission of one night or less) accounted for 2.659 million hospitalizations in 2012 [16]. Inappropriate inpatient stays resulted in Medicare incorrectly paying for 23,148 beneficiaries’ skilled nursing facility (SNF) services, errors estimating to cost the program $255 million [16]. The 2-midnight rule was implemented on October 1, 2013 and redefined the time recommendations for when to admit a beneficiary as an inpatient and when to appropriately use observation services. Inpatient stays were defined as hospital visits that were expected to span at least two midnights or were on a list of inpatient-only conditions. Observation services were still expected to last less than 24 hours, except in rare circumstances, and be used as a tool for physicians to determine if inpatient admission is necessary [16].  The policy explicitly stated the final determination for inpatient admission versus observation status was left to the discretion of the reporting physician, but the policy also stated that CMS could reject payment for inappropriate short stays. Recovery Audit Contractors (RACs), created through the MMA of 2003, are the programs that evaluate the legitimacy of short inpatient admissions and if payment from Medicare is warranted. 
CMS offered trainings on the new policy, and through feedback from providers developed updates to the 2-midnight rule that were announced on October 30, 2015 [17]. The updates did not change the process for stays expected to last more than two midnights, but softened their stance on what was considered an inappropriate inpatient admission. Physicians are now permitted to admit a beneficiary as an inpatient for stays under the two-midnight benchmark provided that there is adequate documentation that inpatient admission is medically necessary [17]. These short inpatient admissions are still subjected to review. 
1.7	Diagnosis Codes
To evaluate the effects of Act 92, it is necessary to use diagnosis codes for illnesses that are commonly treated as inpatient and outpatient because these are the codes that are most likely to utilize observation services – allowing the physician time to determine if inpatient admission is necessary. Act 92 has the potential to cause the most impact among such diagnosis codes. An article focused on a population of Medicare beneficiaries found certain diagnosis codes, such as chest pain, digestive disorders, and fainting, frequently received observation services and short inpatient stays (defined as being admitted as an inpatient lasting less than two nights) [18]. The effect of the creation of observation services from the enactment of Act 92 should be observed in diagnosis codes similar to codes mentioned in the aforementioned study. Act 92 aims to decrease the prevalence of short inpatient stays for these diagnosis codes, as these patients should now receive observation services when medically necessary. Two diagnosis codes were selected using medical claims data to be used within this study: chronic obstructive pulmonary disease and bronchiectasis and nonspecific chest pain. The following sections will discuss the prevalence and associated costs of these conditions, and details about selection of these codes for this study will be discussed in the methods section. 
1.7.1	Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) occurs when damage to the lungs results in diminished air flow. Some examples of damage to the lungs include a loss of elasticity of the alveoli, and obstruction of the airway due to inflammation or mucus [19]. According to the National Institutes of Health, COPD can be used to describe conditions such as chronic bronchitis, chronic obstructive asthma, and emphysema. In 2008, COPD was responsible for over 120,000 deaths making the disease the third most frequent cause of death  ADDIN EN.CITE [20] in the United States. The same year, COPD and asthma were attributed to $13.1 billion dollars in inpatient hospital stays and $3.1 billion in emergency department visits [21]. A study evaluating surveillance reports from 1999-2011 estimated the prevalence of COPD in individuals aged 25 years and older to be 6.5% (13.7 million individuals), with the prevalence peaking in the 65-74 age group (12.1%), and nearly as high among those 75 and older (11.6%)  ADDIN EN.CITE [22]. In 2010, COPD was the primary diagnosis for 72.0 per 10,000 individuals (1.5 million emergency department visits) over 25 years of age and 32.2 per 10,000 hospitalizations (699,000 hospitalizations) in the United States  ADDIN EN.CITE [22]. In 2010, Medicare beneficiaries had a hospitalization with a primary diagnosis of COPD 312,654 times for a rate of 11.11 per 1,000 Medicare enrollees  ADDIN EN.CITE [22]. A retrospective cohort study of Medicaid beneficiaries in 2007 found no significant association between COPD at time of admission and 30-day mortality, but did find a significant association between length of stay and all-cause 30-day readmission for the 19 chronic conditions included in the CMS Hospital Readmissions Reduction effort  ADDIN EN.CITE [23]. Another retrospective cohort study on claims data found the median time from an index hospitalization case of COPD to a COPD-related rehospitalization to be four months  ADDIN EN.CITE [24].
1.7.2	Bronchiectasis
Bronchiectasis is a condition trademarked by the widening of the airways resulting in an individual having a reduced capacity to clear mucus from their lungs. The prevalence of bronchiectasis increases with age, with there being 27.18 cases of bronchiectasis per 10,000 individuals in the United States [25]. Between 1999-2001, individuals hospitalized with bronchiectasis averaged 2.0 days longer in the hospital and averaged $5,681 more in medical spending than a random sample of individuals hospitalized without a diagnosis of bronchiectasis after matching on age, sex, geographic location, and comorbidities [25]. Between 2000 to 2007, Medicare records showed 117,112 claims of bronchiectasis for 22,296 individuals, averaging 5 claims per person  ADDIN EN.CITE [26]. The prevalence of bronchiectasis among Medicare beneficiaries during the same time period was 110.6 cases per 10,000 individuals  ADDIN EN.CITE [26]. 
A study of inpatient hospital discharge records of eight states from 1993 to 2006 found the median length of stay of this population was six days  ADDIN EN.CITE [27]. This population also had a median cost of $7,827 dollars, and in states with readmission data in 2005 and 2006, a majority of the individuals hospitalized were only hospitalized once (81% and 82%, respectively)  ADDIN EN.CITE [27]. 
Medical claims diagnosis codes group COPD and bronchiectasis into a single code, designated as ‘chronic obstructive pulmonary disease and bronchiectasis’. National surveillance data from 2001 to 2012 in the United States showed the average length of stay for a diagnosis of COPD or bronchiectasis decreased 0.9-1.0 days over the span of the study in all age groups except for individuals ages 18-44 who maintained a relatively constant 4 day length of stay, which was equivalent to the overall 2012 average length of stay in the population. The mean cost of hospitalization increased from $12,521 to $26,647 during the same time period  ADDIN EN.CITE [28]. The age-adjusted readmission rates for individuals who were diagnosed with COPD or bronchiectasis increased from 654-724 readmissions per 100,000 emergency department visits for the population  ADDIN EN.CITE [28]. 
1.7.3	Nonspecific Chest Pain
Nonspecific chest pain is chest pain of unknown origin with multiple potential etiologies such as anxiety, angina, digestive issues, inflammation, or lung diseases [29]. Due to the more broad definition for this diagnosis code, there is less research focused solely on the code. A cross-sectional study conducted in Belgium evaluated the differences between individuals with chest pain who report to the emergency department compared to those who report to a general care practitioner for a period between 1993-1994. Out of the study population, 64.4% reported to the emergency department with chest pain, and the chest pain of these individuals was more likely to be associated with more serious diseases – potentially due to better access to diagnostic measures located in the emergency department compared to a general practice  ADDIN EN.CITE [30]. A more recent prospective cohort study conducted at a hospital in the United Kingdom evaluated the burden of nonspecific chest pain admissions. Over an eight-week period, 42.5% of all admissions for chest pain had a final diagnosis as non-specific chest pain. These individuals had a mean admission stay of 3.8 days and mean cost of admission to be €3,729 ($4,959.57 USD)  ADDIN EN.CITE [31].

2.0 	OBJECTIVE
The overall objective of this study is to examine the effect that Act 92 has on acute care facility hospitalization costs for beneficiaries of the Insurer’s plan in Pennsylvania to determine if there has been a significant cost reduction due to the enactment of the legislation on July 1, 2016. To evaluate the impact on quality of health of the same population, a secondary objective of this study was to evaluate the association between Act 92 and probability of 30-day readmission and total cost of a rehospitalization. As will be noted in the results section, secondary analyses were completed to evaluate the relationship between time period and length of stay for the index hospitalization, length of stay for a rehospitalization, and the probability of inpatient admission. 

3.0 	HYPOTHESIS





The population of this study was comprised of dual-eligible Medicare-Medicaid beneficiaries from a D-SNP health plan based in western Pennsylvania. Dual-eligible Medicare-Medicaid beneficiaries were chosen over Medicaid only beneficiaries to ensure there would be an adequate sample size to calculate statistical significance. Beneficiaries must have reported to an acute care facility in Pennsylvania between August 1, 2015 - January 28, 2016 or August 1, 2016 - January 28, 2017 with a primary diagnosis of chronic obstructive pulmonary disease and bronchiectasis or nonspecific chest pain. The study population (N=1,369 hospitalizations) was identified through health insurance claims from the Insurer. Participants were designated as reporting to an acute care facility before or after the enactment of Act 92 (selection of time periods described in section 4.1.3.1). 

4.1.2	Data Source
The data used in this study were pulled from the claims data of a western Pennsylvania Medicare and Medicaid provider, the Insurer. Within the past decade, the enrollment in D-SNP plans offered by the Insurer has almost doubled, from an average of 24,700 enrollees in 2007 to an average of 47,800 enrollees in 2017 [9]. The Insurer offers two separate D-SNP plans, and offers coverage throughout the state of Pennsylvania, as well as coverage in five additional states. There were over 369,000 Pennsylvanian dual-eligible Medicare-Medicaid beneficiaries in 2012 [11], meaning the Insurer served approximately 13% of the state market at that time.
4.1.3	Exposure
4.1.3.1	Selection of Time Periods
The exposure of interest for this study was reporting to an acute care facility prior to the enactment of Act 92 (pre-period) or afterwards (post-period). The post-period was determined first, as Act 92 was enacted on July 1, 2016. To allow for a one-month window of time for Act 92 to take effect, the claims for hospitalizations included in the post-period began on August 1, 2016. The post-period ended on January 28, 2017 due to two specific reasons: 1) it takes three months for claims data to be fully entered into the Insurer’s database and 2) the study required a one-month follow-up to assess the presence of 30-day readmission. The dataset of claims was generated in June 2017, meaning that all claims were entered up until February 2017. The one-month follow-up meant January 28, 2017 would be the last day for an index hospitalization to have a 30-day readmission entered into the database. The pre-period was selected to cover hospitalizations from August 1, 2015 to January 28, 2016 to reflect the same time period in the year prior to the enactment of Act 92. The same time period during the year was chosen because other studies that evaluate cost paid by the Insurer, adjusted for month of admission to control for any seasonal effects  ADDIN EN.CITE [24]. 
4.1.3.2	Selection of Diagnosis Codes for Study
For the proper evaluation of Act 92, it was important to select diagnosis codes to be used in the study that are typically treated through observation services and inpatient admission. This is because Act 92’s aim is to increase the use of proper observation services. It is not logical to include diagnosis codes that always qualify for inpatient admission, as individuals who have these codes should not be receiving observation services to determine if inpatient admission is warranted. On the opposite end of the spectrum, it does not make sense to include diagnosis codes that are almost exclusively treated as observation services or outpatient because if a diagnosis code is almost exclusively treated with observation services or as an outpatient, it will be more difficult to determine if Act 92 led to the transition of using observation services instead of inappropriate short inpatient admission. In addition, it was also important to use diagnosis codes that had readmissions within the pre- and post- periods to evaluate 30-day readmission as a metric of quality of health care during the hospitalization, the validity of which was evaluated in a Swiss study of avoidable readmission rates  ADDIN EN.CITE [32]. 
To determine the diagnosis codes occurring in the pre- and post-periods that had an even distribution of observation services and inpatient admission, all hospitalizations of individuals who qualified to be included in the study during the pre- and post- period were queried. A table was created that counted the number of times a diagnosis code occurred in each of six categories: 1) inpatient admission in the pre-period, 2) observation status in the pre-period, 3) 30-day readmission in the pre-period, 4) inpatient admission in the post-period, 5) observation status in the post-period, and 6) 30-day readmission in the post-period. 
Diagnosis codes were disqualified from inclusion for six different reasons (Figure 1). If the diagnosis code was not in the top 25 of any of the six categories mentioned above, the code was eliminated from inclusion because this study will be able to better evaluate the associations between time period and the outcomes of interest within diagnosis codes that occur frequently within the population. This criterion eliminated 190 diagnosis codes. An additional 17 diagnosis codes were eliminated from potential inclusion in this study because the diagnosis code contained missing data for at least one of the six predetermined categories. Missing data in any of the six categories would result in the inability to compare the outcome between the pre-period and the post-period. Any code that included vague terminology such as ‘residual’ or ‘other’, which constituted 8 of the remaining diagnosis codes, were excluded. As this is one of the first evaluations of the impact of Act 92, it would be better to evaluate the impact of Act 92 among better defined diagnosis codes. An additional 11 diagnosis codes were eliminated due to a minimal number of hospitalizations in one of the six predefined categories. The cutoff point for this designation was if the number of hospitalizations in one or more categories was less than 0.01% of the total number of hospitalizations for the diagnosis code. These diagnosis codes were not included for a similar reason for the missing data exclusions, as there are not enough qualifying events for that category to analyze the associations between time period and the outcome of interest. To maximize sample size of the study, 11 diagnosis codes were eliminated because the overall number of hospitalizations for a diagnosis code across all six categories was less than 300, and an additional three diagnosis codes were eliminated if any individual category contained less than 10 hospitalizations. This process eliminated all but two diagnosis codes: chronic obstructive pulmonary disease and bronchiectasis and nonspecific chest pain and resulted in a final study size of 1,369 qualifying hospitalizations.

Figure 1: Diagram of the number codes that were billed for during the study periods and the number of diagnosis codes that were removed for each disqualification reason.
4.1.4	Outcomes
Three variables were used to analyze any potential changes due to Act 92 on 1) total cost of hospitalization, 2) probability of 30-day readmissions, and 3) total cost of readmission hospitalizations. One, index hospitalization cost, the primary outcome of this study, was measured in U.S. Dollars ($) and was defined as the total cost of claims for a visit to an acute care hospital. 
Two, the probability of readmission within 30 days of the index hospitalization was determined as a measure of consistent healthcare outcomes. This is because if the cost of index hospitalizations decreased significantly and the number of 30-day readmissions increases, it would be more difficult to determine the effects of Act 92 on the study population. For this study, readmission was defined as reporting to an acute care facility within 1 to 30 days after discharge from the individual’s index hospitalization. The readmission hospitalization must also have a diagnosis code of chronic obstructive pulmonary disease and bronchiectasis or nonspecific chest pain. The diagnosis codes for rehospitalization were restricted to the same codes used to identify index hospitalizations because we wanted a measure of any potential changes in health outcomes between the pre- and post- time periods. This is because a meta-analysis of 30-day readmission rates found only 23.1% of readmissions to be avoidable [33]. Measuring the probability of readmission including other diagnosis codes would not be an accurate reflection of true readmission due to care related to the index hospitalization. An example would be an individual with a diagnosis of nonspecific chest pain who was brought back to the hospital within 30 days of being released due to a car accident. This readmission hospitalization had no relation to any care given to the beneficiary during the index hospitalization. 
Three, the cost of a qualifying rehospitalization within 30 days of discharge from the index hospitalization was evaluated to see if the enactment of Act 92 affected all hospitalizations or if the effects differed between index hospitalization and readmissions. 
4.1.5	Other Variables
In addition to the main variables of interest, information was obtained on age, gender, race/ethnicity, index hospitalization length of stay, time from index hospitalization until readmission, type of admission, and if the individual reported to the emergency room for their hospitalization. Comorbidity data were collected to track if the individual received dialysis services, had a history of smoking, severe and persistent mental illness, bipolar disorder, congestive heart failure, depression, diabetes, HIV, lipid metabolic conditions, ischemic heart conditions, osteoporosis, Parkinson’s Disease, persistent asthma, rheumatoid arthritis, schizophrenia, COPD, or chronic renal failure. 
Information on age, gender, and ethnicity were of interest to gather baseline demographic characteristics within the study population. Age was measured as a continuous variable, in years, while the rest were categorical variables. The index hospitalization length of stay, type of admission, diagnosis code at time of admission, and if the individual reported to the emergency department for their hospitalization were gathered for index hospitalizations and qualifying readmissions. These variables were used as baseline characteristics of hospital visits, allowing for comparison among hospitalizations. In addition, these variables are related to the cost of hospitalization.  Length of stay was recorded as a continuous variable measured in days, while admission type, diagnosis code, and reporting via the emergency department were all categorical variables. Reporting to the hospital via the emergency department is an important metric as in 2012, 78% of Medicare beneficiary observation stays started in this department [16]. 
The collection of the comorbidity variables allowed for comparison between individuals and were of interest because comorbidities can affect the severity of disease or the motivation of a physician to admit a patient instead of having the patient be observed. All comorbidities were recorded as a dichotomous variable (present versus not present), and a continuous variable was created to account for the total number of comorbidities. This sum of comorbidities variable was used in the analyses. 
4.1.6	Variables Excluded from the Study
For all analyses, a history of severe and persistent mental illness was not included due to 27% of the study population missing data for this variable. To avoid over-adjustment within the analyses, the individual comorbidities were combined into a continuous variable that was a sum count of the number of comorbidities an individual had record of in his/her claims data (ranging from 0-17). Smoking history was not used due to the nature of the claims data available. The smoker variable was a categorical variable with a value of 1 if an individual had a history of a claim related to a smoking cessation drug, and had a value of 0 otherwise. This meant that the variable would indicate individuals who were trying to quit smoking, and grouped together current smokers and non-smokers into the same category, resulting in a variable that was an inaccurate representation of smoking status.  
4.2	Primary Analyses
Index hospitalization cost and rehospitalization cost were evaluated by the total cost of the hospital visit listed within the claims data. To evaluate 30-day readmission, individuals in the study were marked as either 0 (no hospitalization within 30 days of the index hospitalization) or 1 (reported to the hospital within 30 days for a case that met the definition of rehospitalization). 
Linear regressions were used to compare total costs between the pre- and post- periods for the index hospitalization cost and readmission hospitalization cost. The linear regression model for the index hospitalization cost between the pre- and post- periods was adjusted for type of admission, diagnosis code, age, gender, ethnicity, length of stay of the hospitalization, if the individual reported through the emergency room, and the total number of comorbidities. The linear regression for the rehospitalization cost was adjusted for all of the variables in the index hospitalization cost model plus the length of stay of the readmission hospitalization, the number of days between the index and readmission hospitalizations, and the index hospitalization cost. 
Logistic regression was used to determine the probability of readmission before the enactment of Act 92 compared to after the law took effect. The logistic regression modeling the probability of being readmitted within 30 days of the index hospitalization was adjusted for type of admission, diagnosis code, age, gender, ethnicity, length of stay of the index hospitalization, index hospitalization cost, if the individual reported through the emergency room, and the total number of comorbidities. To calculate statistical significance, an alpha value of 0.05 was used for all p-values. SAS Enterprise (SAS Enterprise Guide 7.1, SAS Institute Inc., Cary, NC, USA) was used for all data analysis.  
It is important to note there were 1,369 hospitalizations that qualified to be included in the study, but not 1,369 unique individuals in the study population. The number of times that an individual reported to the hospital with a qualifying diagnosis code ranged from 1 to 13 times. While some people (N=886, 64.72% of hospitalizations) only reported once throughout the whole study time, the rest (N=483, 35.28% of hospitalizations) reported multiple times within the same time period, once within both time periods, or a combination of multiple hospitalizations within both time periods. To address duplicity of individuals within the study, hospitalization analyses were run for the overall population, for those who only reported to the hospital once throughout the enter study (Never Readmitted), and for those who reported to the hospital more than once (Readmitted). Regressions were only run for the overall and readmitted groups to assess probability of 30-day readmission because the never readmitted group was a sub-population that never had a qualifying readmission hospitalization. The models were run for the readmitted group in addition to the overall group to determine if associations with 30-day readmission changed when evaluating the sub-population that was readmitted. 
For the analysis of the total cost of a readmission hospitalization, only the sub-population who were readmitted were included within the regression model. The aim was to evaluate the association between time period and the cost of rehospitalization, including those who were never readmitted in the regression model would dilute any associations between the variables included in the model and total cost of rehospitalization. 



























Table 1: Set up of the regressions models used in the primary analyses, noting the dependent variable, frequency of duplicate measures, diagnosis code grouping, regression method, independent variable, covariates, and the total number of regression models run for the analyses.

Dependent Variable	Applicable Duplicate Groups	Diagnosis Code Groups	Regression Method	Independent Variable	Covariates	Total Number of Regression Models
Cost of Index Hospitalization	OverallNever ReadmittedReadmitted	OverallCOPD & BronchiectasisNonspecific Chest Pain	Generalized Linear	Time Period	Admission Type1Diagnosis Code2AgeGender3Ethnicity4Index Length of Stay,Report via ED5Sum of Comorbidities	9
30-Day Readmission	Overall Readmitted	OverallCOPD & BronchiectasisNonspecific Chest Pain	Logistic	Time Period	Admission Type1Diagnosis Code2AgeGender3Ethnicity4Index Length of Stay,Report via ED5Index CostSum of Comorbidities	6
Cost of Readmission Hospitalization	Readmitted	OverallCOPD & BronchiectasisNonspecific Chest Pain	Generalized Linear	Time Period	Admission Type1Diagnosis Code2AgeGender3Ethnicity4Index Length of Stay,Report via ED5Sum of Comorbidities,Readmission Length of Stay,Number Days until Readmission,Index Cost,Readmission Diagnosis Code6	3
1     0 = Observation Services, 1 = Inpatient Admission
2   0 = Nonspecific chest pain, 1 = COPD and bronchiectasis
3   0 = Male, 1 = Female
4   0 = Referent = White, African American = 1, Hispanic = 1, Other Race = 1
5   0 = Did not report to hospital through ED, 1 = Reported to hospital through ED
6   Diagnosis code used as a covariate in overall diagnosis code models only
5.0 	SECONDARY ANALYSES
Secondary analyses were completed to further explore the associations of the pre- and post-period with the length of stay of a hospitalization as there is a consistent significant relationship between length of stay and the total cost of hospitalization. It was hypothesized that length of stay would decrease in the post-period compared to the pre-period for index hospitalizations and rehospitalizations. This is because Act 92 aimed to increase observation services, which are shorter in duration than inpatient admission. The probability of inpatient admission between the pre- and post-periods was also explored, as observation services are associated with a shorter length of stay. The time periods were defined in the same way as the primary analyses. 
There were three main outcomes evaluated in the secondary analyses: 1) length of stay for the index hospitalization, 2) length of stay for a readmission hospitalization, and 3) probability of inpatient admission compared to observation services. 
Index and readmission hospitalization length of stay were continuous variables measured in days. Individuals’ hospital status was measured as a dichotomous variable, either 0 (outpatient status) or 1 (admitted as an inpatient) for the duration of their hospital stay. The same variables and subpopulations of readmission status and diagnosis codes used in the primary analyses were used in the secondary analyses. This resulted in 21 total regression models being run to evaluate the association between time period and the three outcomes of the secondary analyses (Table 2).  

































Table 2: Set up of the regression models used in the secondary analyses, noting the dependent variable, frequency of duplicate measures, diagnosis code grouping, regression method, independent variable, covariates, and the total number of regression models run for the analyses.

Dependent Variable	Applicable Duplicate Groups	Diagnosis Code Groups	Regression Method	Independent Variable	Covariates	Total Number of Regression Models
Index Hospitalization Length of Stay	OverallNever ReadmittedReadmitted	OverallCOPD &BronchiectasisNonspecific Chest Pain	Generalized Linear	Time Period	Admission Type1Diagnosis Code2AgeGender3Ethnicity4Report via ED5Sum of Comorbidities	9
Readmission Hospitalization Length of Stay	Readmitted	OverallCOPD & BronchiectasisNonspecific Chest Pain	Generalized Linear	Time Period	Admission Type1Diagnosis Code2AgeGender3Ethnicity4Index Length of StayReport via ED5Sum of Comorbidities,CostReadmission Diagnosis Code6	3
Probability of Inpatient Admission	OverallNever ReadmittedReadmitted	OverallCOPD & BronchiectasisNonspecific Chest Pain	Logistic	Time Period	Diagnosis Code2AgeGender3Ethnicity4Report via ED5Sum of Comorbidities	9
1     0 = Observation Services, 1 = Inpatient Admission
2   0 = Nonspecific chest pain, 1 = COPD and bronchiectasis
3   0 = Male, 1 = Female
4   0 = Referent = White, African American = 1, Hispanic = 1, Other Race = 1
5   0 = Did not report to hospital through ED, 1 = Reported to hospital through ED




Among all hospitalizations, half occurred in the pre-period and half in the post-period. There was a statistically significant decrease in index hospitalization cost between the pre- and post- periods in the overall, never readmitted, and readmitted models when evaluating all diagnosis codes. Other variables that were significantly different among at least one of these three models were a decrease in age in the overall population and an increase in white individuals and decrease in all other race ethnicities in the overall readmitted population. An increase in nonspecific chest pain and observation services were observed in the overall and never readmitted overall populations (Table 3).  In the same categories, a decrease in COPD, inpatient admission, and the sum of comorbidities were also observed from the pre- to post-period (Table 3).
Among all hospitalizations for nonspecific chest pain, more occurred in the post-period than the pre-period. There were no variables that were statistically significant in all three admission type models. Variables significantly different in at least one of the models were race/ethnicity, type of admission, and sum of comorbidities (Table 11, Appendix).




Table 3: Descriptive characteristics of the pre-period and post-period for the overall study population, with p-values provided for each breakdown of the overall, never readmitted, and readmitted populations with both diagnosis codes.
Variable	Overall Population	Overall Never Readmitted Population	Overall Readmitted Population
	Pre-Period(n=689)	Post-Period(n=680)	P-value	Pre-Period(n=450)	Post-Period(n=436)	P-value	Pre-Period(n=239)	Post-Period(n=244)	P-value
Age (years)	65.0 (57.0, 72.0)	64.0 (56.0, 71.0)	0.0268*	66.0 (57.0, 73.0)	65.0 (56.0, 72.0)	0.1459	63.0 (57.0, 71.0)	61.0 (56.0, 69.0)	0.0784
Gender (%, n)    Male    Female	51.00 (280)49.88 (409)	49.00 (269)50.12 (411)	0.6836	50.63 (162)50.88 (288)	49.38 (158)49.12 (278)	0.9411	51.53 (118)47.64 (121)	48.47 (111)52.36 (133)	0.3931
Race/Ethnicity (%, n)    White    African American    Hispanic/Latino    Other	48.93 (435)52.41 (174)54.46 (61)52.78 (19)	51.07 (454)47.59 (158)45.54 (51)47.22 (17)	0.5475	50.71 (284)52.83 (112)45.78 (38)51.61 (16)	49.29 (276)47.17 (100)54.22 (45)48.39 (15)	0.7541	45.90 (151)51.67 (62)79.31 (23)60.00 (3)	54.10 (178)48.33 (58)20.69 (6)40.00 (2)	<0.0001*
Index Diagnosis (%, n)    Chest Pain    COPD	43.44 (139)52.43 (550)	56.56 (181)47.57 (499)	0.0049*	40.80 (102)54.72 (348)	59.20 (148)45.28 (288)	0.0002*	52.86 (37)48.91 (202)	47.14 (33)51.09 (211)	0.5414
Type of Admission (%, n)    Observation    Inpatient	39.39 (78)52.18 (611)	60.61 (120)47.82 (560)	0.0009*	35.37 (52)53.86 (398)	64.63 (95)46.14 (341)	<0.0001*	50.98 (26)49.31 (213)	49.02 (25)50.69 (219)	0.8210
Cost of Index Hospitalization ($ USD)	5,580.86(3,873.77, 6,872.74)	4,878.66(3,276.78, 6,040.29)	<0.0001*	5,405.74(3,846.76, 6,700.93)	4,756.46(2,861.35, 6,006.02)	<0.0001*	5,790.83 (3,914.99, 7,093.48)	5,005.01(3,537.76, 6,151.21)	0.0007*
Index Hospitalization LOS (days)	3.0 (2.0, 5.0)	3.0 (1.0, 4.0)	0.0816	3.0 (1.0, 4.0)	3.0 (1.0, 4.0)	0.1273	3.0 (2.0, 5.0)	3.0 (2.0, 5.0)	0.3133
Came through ED (%, n)	50.51 (640)	49.49 (627)	0.6307	51.10 (419)	48.90 (401)	0.5187	49.44 (221)	50.56 (244)	0.9485
Readmitted (%, n)	53.33 (48)	46.67 (42)	0.5507	-	-	-	53.33 (48)	46.67 (42)	0.4025
Time until Readmission (days)	12.0(3.0, 23.0)	13.0 (5.0, 22.0)	0.6528	-	-	-	12.0 (3.0, 23.0)	13.0 (5.0, 22.0)	0.6528
Readmission Diagnosis (%, n)     Chest Pain    COPD	47.62 (10)55.00 (44)	52.38 (11)45.00 (36)	0.5462	-	-	-	47.62 (10)55.00 (44)	52.38 (11)45.00 (36)	0.5462
Cost of Readmission Hospitalization ($ USD)	5,056.29(0.00, 7,399.46)	4,690.15(0.00, 5,866.54)	0.2219	-	-	-	5,056.29 (0.00, 7,399.46)	4,690.15(0.00, 5,866.54)	0.2219
Readmission Hospitalization LOS (days)	3.0 (1.0, 5.0)	2.0 (1.0, 5.0)	0.4560	-	-	-	3.0 (1.0, 5.0)	2.0 (1.0, 5.0)	0.4560
Sum Comorbidities (# of comorbidities)	7 (5, 8)	6 (5, 8)	0.0001*	6 (5, 8)	6 (4, 7)	<0.0001*	7 (5, 8)	7 (5, 8)	0.1965
Individual tables with descriptive characteristics can be found in the appendix (Tables 11 and 12).




6.1.2	Index Hospitalization Cost Regression Analyses
As expected, length of stay was associated with a statistically significant increase in index hospitalization cost for all nine models (Table 4, Tables 13-14, Appendix). This was the only variable of significance in all models, and it was associated with an increase in cost ranging from $273 to $870 per additional day spent at the hospital. For the overall and readmitted overall models, observation status was significantly associated with a decrease in index hospitalization cost of $1,219 - $2,221. A diagnosis of COPD and bronchiectasis was associated with a statistically significant $721 - $858 increase in total index hospitalization cost in the overall and never readmitted overall models (Table 4). 
Among overall chest pain and never readmitted chest pain models, age was associated with a significant decrease in cost ranging from $32 - $36 per year increase in age (p = 0.0163 - 0.0020). Reporting to the hospital via the emergency department was associated with a statistically significant increase in index hospitalization cost ranging from $535 - $1,334 (p = 0.0089 – 0.0142) (Table 13, Appendix). 
Two models with a diagnosis code of COPD and bronchiectasis were significantly associated with observation status. In these models, overall COPD and bronchiectasis and readmitted COPD and bronchiectasis, observation status was associated with a decrease in index hospitalization cost ranging from $2,644-$3,110 compared to inpatient admission. The only other variable significantly associated with index hospitalization was time period in the readmitted COPD and bronchiectasis model, where reporting to the hospital in the pre-period was associated with a $796 increase in index hospitalization cost compared to reporting during the post-period (p = 0.0156) (Table 14, Appendix).
Table 4: Significant variables for the overall, never readmitted overall, and readmitted overall index hospitalization cost regression models.

Model	Total R2	Significant Associations	Standardized regression coefficient	P-value
Overall	0.253527	Observation StatusCOPD DiagnosisLength of Stay	-1,219.99721.31558.27	0.00070.0138<0.0001
Never Readmitted Overall	0.312407	COPD DiagnosisLength of Stay	858.77764.25	0.0179<0.0001
Readmitted Overall	0.197011	Observation StatusLength of Stay	-2,221.36333.59	0.0002<0.0001
6.1.3	Probability of Readmission within 30 Days Regression Analyses
The probability of being readmitted within 30 days of the index hospitalization significantly decreased per year increase in age, and for females compared to males. The probability of being readmitted significantly increased per additional comorbidity for a beneficiary.
 Being female was the only variable that was significantly associated with the probability of readmission (p=0.0185 - <0.0001) in all models that were able to calculate the maximum likelihood estimate (Table 5). Models where the maximum likelihood estimate may not exist may be due to subgroups of categorical variables within the models where all beneficiaries were readmitted or all were never readmitted.  An example in this study were the maximum likelihood estimate would not be satisfied would be in the readmitted chest pain models, where all Hispanic/Latino individuals who were readmitted were readmitted in the pre-period, and none in the post-period.
Depending on the model, females had 59% - 83% lower odds of being readmitted compared to males. In addition, for each additional comorbidity, the odds of a 30-day readmission increased by 1.178-1.420 times (p=0.0028-0.0359) (Table 5). 

Table 5: Significant associations with being readmitted within 30 days of the index hospitalization.
Model	Significant Associations	Standardized regression coefficient	Odds Ratio (95% CI)	P-value
Overall	AgeFemaleSum Comorbidities	-0.0282-0.58960.1634	0.972 (0.951, 0.994)0.308 (0.194, 0.487)1.178(1.058, 1.310)	0.0125<0.00010.0028
Overall Nonspecific Chest Pain*	FemaleSum Comorbidities	-0.88780.3506	0.169 (0.039, 0.742)1.420 (1.030, 1.957)	0.01850.0322
Overall COPD and Bronchiectasis *	AgeFemaleSum Comorbidities	-0.0262-0.56710.1650	0.974 (0.951, 0.998)0.322 (0.197, 0.526)1.179 (1.049, 1.326)	0.0359<0.00010.0059
Readmitted Overall	Female	-0.4446	0.411 (0.250, 0.675)	0.0004
Readmitted Nonspecific Chest Pain*	None	-	-	-
COPD and Bronchiectasis *	Female	-0.4429	0.412 (0.243, 0.701)	0.0011
* Maximum likelihood estimate may not exist
6.1.4	Rehospitalization Cost Regression Analyses
Among individuals who had a qualifying rehospitalization within 30 days of the index hospitalization, only the length of stay of the readmission hospitalization was significantly associated with the total cost of readmission in the readmitted overall and readmitted COPD and bronchiectasis models. Each additional day spent in the hospital was associated with an increase of total cost ranging from $503.69 to $530.52 (Table 6).

Table 6: Significant variables for the cost of rehospitalization models.
Model	Total R2	Significant Associations	Standardized regression coefficient	P-value
Readmitted Overall	0.287570	Readmit Length of Stay	503.69	0.0016
Readmitted Nonspecific Chest Pain	0.923964	None	-	-
Readmitted COPD  and Bronchiectasis	0.224279	Readmit Length of Stay	530.52	0.0036
6.2	Summary of Primary Analyses
The overall findings of the index hospitalization cost and rehospitalization cost models showed a consistently significant association of length of stay of the respective hospitalization with total cost, while time period was not significantly associated with cost of index hospitalization nor the cost of rehospitalization (Table 4, Tables 13 and 14, Appendix). The findings suggest that any significant association between cost of hospitalization and reporting to the hospital in the pre-period compared to the post-period could be overshadowed by the association between total cost of hospitalization and length of stay (Table 4, Tables 13 and 14, Appendix). A positive linear relationship between length of stay and total cost was expected, as it is logical that the longer an individual is hospitalized the higher their cost (Table 4, Tables 13 and 14, Appendix). Thus, secondary analyses were conducted after the primary analyses to evaluate any potential significant associations between length of stay and the pre- and post-periods. These results will be discussed in the next section.  
As with total cost of hospitalization, reporting to the hospital before versus after Act 92 was not significantly associated with the likelihood of readmission within 30 days (Table 5). The primary significant association with increased probability of readmission was the number of comorbidities, while being female was associated with a decrease in readmission probability (Table 5). Time period was only significant in one out of 18 models evaluating the total cost of an index hospitalization, where reporting to the hospital in the pre-period for individuals who reported to the hospital at least twice with a diagnosis of COPD and bronchiectasis was associated with a $796 increase in total cost of the hospitalization (Table 14, Appendix). 
6.3	Secondary analyses Results	 
6.3.1	Index Hospitalization Length of Stay Regression Analyses
Among all models estimating the length of stay for the index hospitalization, receiving observation services was significantly associated with a 2.32 - 4.13 days shorter stay compared to inpatient admission (Table 7, Appendix Tables 6-7). Individuals diagnosed with COPD and bronchiectasis had significantly longer length of stay compared to those diagnosed with nonspecific chest pain (p < 0.0001 for all three models), with a hospitalization stay ranging from 1.21 - 1.37 days longer. Reporting to the hospital via the emergency department was significantly associated with a 0.72 – 0.94 day decrease in length of stay for the overall and overall never readmitted models (p = 0.0028 – 0.0109). Other variables that had a significant association with length of stay in the overall models were sum of comorbidities, being female, and being African American (Table 7).
There was only one other significant association in nonspecific chest pain models. Each increase in the number of comorbidities was associated with a 0.11-day increase of the index hospitalization length of stay in the overall chest pain model (p = 0.0175) (Table 15, Appendix). Among individuals who had a diagnosis of COPD and bronchiectasis, reporting to the hospital via the emergency department was associated with a 0.98 - 1.23 day decrease in length of stay for the index hospitalization in the overall and never readmitted models (p = 0.0042 - 0.0064) (Table 16, Appendix). Other variables that had a significant association in the never readmitted models were being female, associated with an increase in length of stay, and being African American, which was associated with a decrease in length of stay (Table 16, Appendix). 
Table 7: Significant variables for the length of stay, in days, of the index hospitalization for models included both diagnosis codes.

Model	Total R2	Significant Associations	Standardized regression coefficient	P-value
Overall	0.218881	Observation StatusCOPD DiagnosisReport via EDSum Comorbidities	-2.781.29-0.720.07	<0.0001<0.00010.01090.0333
Never Readmitted Overall	0.277800	Observation StatusCOPD DiagnosisFemaleAfrican AmericanReport via ED	-2.691.210.43-0.52-0.94	<0.0001<0.00010.01420.00950.0028
Readmitted Overall	0.150466	Observation StatusCOPD Diagnosis	-3.151.37	<0.00010.0022

6.3.2	Rehospitalization Length of Stay Regression Analyses








Table 8: Significant variables for readmission hospitalization length of stay models.
Model	Total R2	Significant Associations	Standardized regression coefficient	P-value
Readmitted Overall	0.278365	Other RaceSum ComorbiditiesIndex Length of Stay	7.210.50.33	0.01020.00570.0051
Readmitted Nonspecific Chest Pain	0.761079	None	-	-
Readmitted COPD and Bronchiectasis	0.257702	Other RaceSum ComorbiditiesIndex Length of Stay	7.200.530.31	0.01190.00910.0103

6.3.3	Probability of Inpatient Admission Regression Analyses
The time period during which a beneficiary reported to the hospital was significantly associated with the probability of inpatient admission. For the overall model, overall chest pain model, and never readmitted overall model, individuals hospitalized after the enactment of Act 92 were 32.7%-42.1% less likely to be admitted as an inpatient compared to individuals hospitalized prior (Table 9, Tables 17 and 18, Appendix). This can be interpreted as an increase in the use of observation services, as individuals in the study were only classified as either inpatient admission or observation services. 
A diagnosis of COPD and bronchiectasis compared to nonspecific chest pain had the largest increase in odds of being admitted as an inpatient compared to receiving observation services. Being diagnosed with COPD was associated with a significant 15 - 56 increase in odds of being admitted as an inpatient (Table 9). Individuals who were Hispanic or Latino had a statistically significant reduction in probability of being admitted as an inpatient in the overall, overall nonspecific chest pain, never readmitted overall, and never readmitted COPD and bronchiectasis models, meaning that these individuals were less likely to be admitted as an inpatient compared to white individuals (OR = 0.336-0.469, p = 0.0012 -0.0284) (Table 9, Tables 17 and 18, Appendix). Among the overall, never readmitted overall, and readmitted overall models, the sum of comorbidities was significantly associated with a 15.6% - 22.5% increase in the odds of being admitted as an inpatient compared to being treated through observation services (Table 9).
The sum of comorbidities was also significantly associated with the probability of inpatient admission in the overall nonspecific chest pain and never readmitted chest pain models. Each additional comorbidity was associated with an 18% increase in odds of being admitted as an inpatient compared to being treated with observation services (Table 17, Appendix).  
Among individuals with a diagnosis of COPD and bronchiectasis, reporting to the hospital via the emergency department was associated with a 6.223 - 25.859 increase in odds of being admitted as inpatient compared to receiving observation services (p < 0.0001 for both models of significance) (Table 18, Appendix). 

Table 9: Significant variables for the probability of being admitted as an inpatient compared to receiving observation status.

Model	Significant Associations	Standardized regression coefficient	Odds Ratio	P-value
Overall	After Time PeriodCOPD DiagnosisHispanic Report via EDSum Comorbidities	-0.19781.67190.14980.39930.1452	0.673 (0.455, 0.995)28.327 (18.558, 43.238)0.420 (0.236, 0.747)2.222 (1.144, 4.316)1.156 (1.059, 1.263)	0.0472<0.00010.00310.01840.0012
Never Readmitted Overall	After Time PeriodAfrican AmericanHispanicReport via ED
Sum ComorbiditiesCOPD Diagnosis 	-0.27330.3223-0.54490.54820.14692.0142	0.579 (0.352, 0.952)1.905 (1.039, 3.494)0.336 (0.165, 0.684)2.994 (1.265, 7.084)1.158 (1.035, 1.296)56.172 (29.607, 106.574)	0.03140.03720.00260.01260.0104<0.0001
Readmitted Overall	Sum ComorbiditiesCOPD Diagnosis	0.20321.3404	1.225 (1.035, 1.451)14.596 (6.978, 30.529)	0.0184<0.0001
6.4	Summary of Secondary Analyses
Secondary analyses to evaluate the association between time period and length of stay showed no statistically significant association. Among the linear regression models examining the index length of stay, observation status was associated with a statistically significant decrease in index length of stay for all models (Table 7, Tables 15 and 16, Appendix). Among the models evaluating the associations with rehospitalization length of stay, comorbidities, index length of stay, and being a race other than white, African American, or Hispanic were all associated with a statistically significant increase in length of stay of a rehospitalization (Table 8). 
Examining the probability of inpatient admission was when a statistically significant association with the pre- and post-periods was observed. Reporting to an acute care center during the post-period was associated with a statistically significant decrease in the probability of being admitted as an inpatient compared to the pre-period (Table 9, Tables 17 and 18, Appendix). 

7.0 	DISCUSSION 
This report investigated the impact of Act 92 on six outcomes: total cost of index hospitalization, probability of readmission within 30 days, total cost of rehospitalization, index hospitalization length of stay, readmission hospitalization length of stay, and the probability of inpatient admission. The regression models in the primary analyses showed there was not a statistically significant association between time period and cost of hospitalization for the index hospitalization and readmission hospitalization models. This relationship was consistent among all models, and applied to all diagnosis codes and population breakdowns (entire study population, never readmitted sub-population, and readmitted sub-population). As expected, a significant positive association was found between the total cost of an index hospitalization and length of stay, regardless of diagnosis type or readmission status. In the primary analyses, age and reporting via the emergency department were significant among individuals diagnosed with nonspecific chest pain. Individuals diagnosed with COPD and bronchiectasis had significant associations with the pre-period and readmission length of stay, associations that were not observed among those diagnosed with nonspecific chest pain. 
Secondary analyses to further explore the relationship between time period and length of stay found a significant association between receiving observation services and a shorter length of stay, also regardless of diagnosis or readmission. Individuals who remained as outpatients instead of being admitted had a shorter index length of stay, and thus a lower total cost of index hospitalization. In the secondary analyses, individuals diagnosed with COPD and bronchiectasis had significant associations with gender, race, reporting to the hospital through the emergency department that were not observed in individuals diagnosed with nonspecific chest pain. A significant association between the post-period and a reduction in the likelihood of being admitted as an inpatient, an association observed in the overall model, was observed among individuals diagnosed with nonspecific chest pain only. The sum of comorbidities was significant for individuals diagnosed with nonspecific chest pain when evaluating the index hospitalization length of stay and probability of inpatient admission, and was significant for individuals diagnosed with COPD and bronchiectasis when evaluating the readmission hospitalization length of stay. 
Act 92 is having the desired effect on this study population. The results observed may be due to an increase in observation services, which is associated with a decrease in length of stay. A decrease in length of stay is associated with a decrease in total cost of hospitalization. This means individuals who report to an acute care facility in the post-period are more likely to receive observation services, and individuals who receive observation services stay in the hospital for a shorter duration, thus having a lower total cost. This relationship between time period, cost, and health outcomes is complex. Joining the results of the models suggests the statistically significant difference in median total cost in the pre-period versus the post-period seen in the descriptive characteristics may be due to Act 92. 
Some significant variables for each outcome differed between nonspecific chest pain and COPD and bronchiectasis models. It is important to note that while sometimes a variable would be significant for models with one diagnosis code and not the other, there were no instances of a reversal in the direction of the association between diagnosis code models when the variable was significant for both codes. This indicates the impact of Act 92 can differ between diagnosis codes, and it is important to note the potential for diagnosis codes excluded from this study to see a greater increase in the use of observation services, or even a reduction in observation services. 
7.1	Limitations
This study had several limitations: 1) no usable data on smoking status, 2) repeat observations, 3) a lack of a control group, 4) having a dual-eligible population instead of a Medicaid only population, 5) related but differentiated diagnosis codes will be missed in the assessment of readmission, 6) overall results weighted towards the results of the chronic obstructive pulmonary disease and bronchiectasis diagnosis, and 7) limited generalizability. 
One, smoking is a risk factor for COPD, in which the use of cigarette, pipes, cigars, and exposure to secondhand smoke are all common causes of COPD [19] and cardiac events [34]. A study of smoking bans in public areas, such as restaurants and workplaces, in 32 states throughout the United States found such bans were associated with reduced risk-adjusted hospital admission rates for acute myocardial infarction and COPD  ADDIN EN.CITE [35]. This study was conducted among Medicare beneficiaries over almost two decades, from 1991 to 2008  ADDIN EN.CITE [35]. This suggests that individuals who are not exposed to smoke are at a decreased risk of hospitalization for these two conditions. Therefore, not being able to adjust for current or past smoking could bias the observed relationships.  
Two, being admitted to the hospital in the before and after time periods, as well as being admitted more than once within the same time period, reduced the reliability and introduced replicate observations into the models. This study evaluated the associations of the independent variables and the outcomes of interest in the overall population, the never readmitted population, and readmitted population. The never readmitted population models produced valid regression coefficients as all individuals in this population were only hospitalized once during the entire study period. The overall and readmitted models have within subject correlations due individuals being hospitalized multiple times within the same time period, and between group correlation due to individuals who were hospitalized in the pre-period and post-period. The multiple hospitalizations invalidate the independent observations assumptions of the regression models in this study. This means that the regression coefficients from the overall and readmitted models are in general valid, but the standard error measurements are typically smaller or larger than the true variability. Since standard errors are used in the calculation of the p-value, the interpretation and inference of the associations in the models may be influenced by the correlations. 
Three, the study lacked a control group of dual-eligible Medicare-Medicaid beneficiaries in another state that does not have a law similar to Act 92. The ability to analyze a control group in another state would allow for comparisons of the rates of observation service use and inpatient admission to determine if the reduction in probability of inpatient admission was seen only in Pennsylvania during this time frame. If the association was not limited to just Pennsylvania, it is indicative that the association observed may be the result of a federal piece of legislations, such as the CMS 2-Midnight rule. 
Four, it is likely that the impact of Act 92 is less on the dual-eligible Medicare-Medicaid population than a Medicaid only population. This is because the primary payer for dual-eligible beneficiaries is Medicare, so a smaller proportion of costs would be paid by Medicaid. Though Act 92 still applies to dual-eligible beneficiaries, Medicaid only beneficiaries would be a better suited population to evaluate the true associations between the pre- and post- periods and the outcomes of interest. 
Five, there exists the potential for related diagnosis codes that would indicate a potentially related health condition can be missed if the codes are different from each other. This could have a greater impact among nonspecific chest pain, which has multiple etiologies [29] . The set-up of this study would result in the scenario where an individual who had an index diagnosis of nonspecific chest pain could be discharged from the hospital and return within 30 days with a different diagnosis and would not be classified as having a readmission. Both of these diagnoses could stem from the initial diagnosis of nonspecific chest pain, but this information would be missed from the study population. 
Six, 76.6% (1,049/1,369 hospitalizations) of the study population had an index diagnosis of chronic obstructive pulmonary disease and bronchiectasis. This means the overall model results could be weighted towards the results of the COPD group, and thus followed the same trends of association as the individual COPD group. This can be seen in the regression models focusing on cost of readmission, readmission length of stay, and probability of being readmitted within 30 days of the index hospitalization. 
Seven, the generalizability of this study is limited. The results can only be applied to dual-eligible Medicare-Medicaid beneficiaries who reside in Pennsylvania and receive their insurance from the Insurer. Results would not apply well to individuals who are wealthy elderly individuals or non-disabled adults as they would qualify to receive Medicare and Medicaid. 

7.2	Strengths
There were also two main strengths of this study: 1) the study had a large age range within the population and 2) the overall model is akin to an intention to treat model. The population of this study ranged in age from 25 to 96 years of age, allowing for the results of all regression models to be applied to an adult disabled population, and low-income beneficiaries.  
Calculating regression models for the overall population and then by diagnosis code allowed for a comparison of significantly associated traits between chronic obstructive pulmonary disease and bronchiectasis and nonspecific chest pain. The overall model assessing significant associations between the pre-period and post-period for both codes together allowed the models to begin to identify significant associations that would occur in an everyday situation. 
In addition, the topic of this study is novel. To our knowledge, there have yet to be any evaluations of the impact of Act 92 on hospitalization costs or health outcomes since it was enacted in July 2016. The results of this study are a promising evaluation of the real-world implications that have resulted from this specific section of the piece of legislation.
7.3	Study Implications FOR Legislation
While this study suggests that Act 92 is having the desired effect of increasing the use of observation services and decreasing the cost of hospitalizations in this population of dual-eligible Medicare-Medicaid beneficiaries, there are still opportunities for further studies to contribute to this evidence. Potential future studies were described in the previous section, and the results of these studies are important to know how the outcomes are affected by the pre-period and post-period within a broader number of diagnosis codes before coming to a decisive conclusion on the benefits, or potential risks, of Act 92. 
It is important to evaluate the changes in total cost, length of stay, and probability of inpatient admission within a dual-eligible Medicare-Medicaid and Medicaid only beneficiaries outside of Pennsylvania during a similar time frame to assess if the associations are consistent. If consistent associations are observed outside of Pennsylvania, it indicates that the decrease in total cost seen in this study may be associated with the implementation of the ACOs or the CMS 2-Midnight Rule.
Other states that may be debating implementing a similar law for their Medicaid population can learn from the enactment of Act 92 in Pennsylvania. By clearly defining and describing the conditions that qualify for observation services, and an accompanying cost scale for observation services, Act 92 was able to appropriately set cost for services in a method that was less than the sum of outpatient procedures. By appropriately setting a guideline range of a minimum of 8 hours and a guideline maximum of 48 hours for observation services [5], Act 92 was designed to allow observation services to be used as intended and not misused by physicians for a duration longer than recommended. The implementation of a review board and the option for the Insurer, and other health insurance providers, to not reimburse for observation stays longer than recommend that are not medically necessary helps the law be implemented correctly. 
7.4	Direction Moving Forward
The variation in significantly associated variables with the six outcomes evaluated in this study suggest that further research should be conducted on this topic within the Medicare-Medicaid population, as dual eligible recipients account for a disproportionate amount of spending for both Medicaid and Medicare [11]. More studies to evaluate the similarities and differences in the association of these variables with the outcomes of interest would strengthen the conclusion that Act 92 is having the desired effect of increasing the prevalence of observation service use, and thus reducing total costs of hospitalization. 
Studies that contain a larger population and more diagnosis codes would allow for a more thorough analysis of variables associated with cost, and the potential impact that Act 92 time periods had on cost paid by the Insurer, 30-day readmission, length of stay, and probability of inpatient admission. Future studies that focus on a longer time period for readmission would also allow for a better assessment of the association of readmission rates and time periods because certain diseases, such as COPD, peak three to four months after an index hospitalization  ADDIN EN.CITE [24]. 
In addition, it would be beneficial to evaluate the effects of this legislation within a Medicaid only population, since that is the population Act 92 was meant to impact. Since dual-eligible beneficiaries are costlier that Medicaid only beneficiaries, and account for a disproportionate cost per beneficiary for Medicaid [11], it is worth evaluating the associations between the outcomes of this study and the pre- and post-periods on Medicaid only beneficiaries. If the observed associations in this study are true associations, conducting this study in a Medicaid only population will stronger significance and drive the associations away from the null hypothesis of no difference between the time periods. 

7.5	Public Health Significance of Act 92
The results of this study indicate that, since the enactment of Act 92, the use of observation services has increased and the median costs of index hospitalizations have decreased. The use of observation services results in a shorter length of stay at an acute care facility, which is associated with lower total costs. This decrease in costs for the Insurer may lead to a decrease in costs to beneficiaries as well through lower copayments. After adjustment, receiving observation services compared to inpatient admission can reduce the total cost of a hospitalization by more than $1,000 per beneficiary, and if the associations found in this study continue there could be an impact on budgets as well. This is because insurance companies, the state government, and federal government will have lower costs for individuals for whom they provide health insurance. These lower costs will only occur if 30-day readmissions remain constant or lower than their current rates, and any readmission related to a shorter stay would negate any initial cost savings from the index hospitalization. 
8.0 	CONCLUSION
























Table 10: Description of observation services, fees, and requirements for different payment levels. All fees are on a per day basis.
Description	Procedure Code	Complexity Level	Severity Level	Time Spent @ Bedside, Floor, and/or Unit (mins)	Provider Type	Provider Specialty	Place of Service	Medical Assistance Fee ($)
Observation care discharge day management	99217	-	-	-	31	All spec	22	36.89
Initial care, per day, for the evaluation and management of a patient which requires these 3 components:1) A detailed or comprehensive history2) A detailed or comprehensive examination3) Medical decision making that is straightforward and of appropriate complexity Counseling and/or coordination of care with other physicians, other qualified health professionals, or agencies are provided with the nature of the problem(s) and the patient’s and/or family’s needs	99218	Low	Low	30	31	All spec	22	50.56
	99219	Moderate	Moderate	50	31	All spec	22	69.14
	99220	High	High	70	31	All spec		94.67
Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 components:1) Problem focused interval history2) Problem focused examination3) Medical decision making that is straightforward and of appropriate complexityCounseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs.	99224	Low	Patient is usually stable, recovering, or improving	15	31	All spec	22	20.44
	99225	Moderate	Patient is responding inadequately to therapy or had developed a minor complication	25	31	All spec		36.87
	99226	High	Patient is unstable or has developed a significant complication of a significant new problem	35	31	All spec	22	53.25
Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date, which requires 3 key components:1) A detailed or comprehensive history2) A detailed or comprehensive examination3) Medical decision making that is straightforward and of appropriate complexityCounseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s)	99234	Low	Low	40	31	All spec	22	69.18
	99235	Moderate	Moderate	50	31	All spec	22	86.29
	99236	High	High	55	31	All spec	22	111.46
(Leesa M. Allen, 2016)
Table 11: Descriptive characteristics of the pre-period and post-period for the overall stud population, with p-values provided for the overall, never readmitted, and readmitted populations for individuals diagnosed with nonspecific chest pain.
Variable	Overall Population	Never Readmitted Population	Readmitted Population
	Pre-Period(n=139)	Post-Period(n=181)	P-Value	Pre-Period(n=102)	Post-Period(n=148)	P-Value	Pre-Period(n=37)	Post-Period(n=33)	P-Value
Age (years)	60.0 (52.0, 71.0)	59.0 (52.0, 69.0)	0.7628	62.0 (53.0, 72.0)	61.5 (52.0, 70.0)	0.5592	56.0 (51.0, 61.0)	54.0 (52.0, 67.0)	0.7456
Gender (%, n)    Male    Female	48.65 (72)38.95 (67)	51.35 (76)61.05 (105)	0.0811	47.57 (49)36.05 (53)	52.43 (54)63.95 (94)	0.0682	51.11 (23)56.00 (14)	48.89 (22)44.00 (11)	0.6946
Race/Ethnicity (%, n)    White    African American    Hispanic/Latino    Other	21.56 (69)43.24 (32)53.70 (29)60.00 (9)	61.02 (108)56.76 (42)46.30 (25)40.00 (6)	0.1434	38.93 (51)38.33 (23)43.18 (19)60.00 (9)	61.07 (80)61.67 (37)56.82 (25)40.00 (6)	0.4346	39.13 (18)64.29 (9)100.00 (10)-	60.87 (28)35.71 (5)0.00 (0)-	0.0014*
Type of Admission (%, n)    Observation    Inpatient	37.42 (61)49.68 (78)	62.58 (102)50.32 (79)	0.0270*	35.07 (47)47.41 (55)	64.93 (87)52.59 (61)	0.0477*	48.28 (14)56.10 (23)	51.72 (15)43.90 (18)	0.5184
Cost of Index Hospitalization  ($ USD)	2,051.00(964.51, 4,215.87)	2,293.72(1,142.54, 4,075.65)	0.7570	2,049.87(934.59, 4,215.72)	2,237.92 (1,172.91, 4,027.95)	0.6236	2,193.90(1,092.96, 4,389.03)	2,595.06(570.46, 4,205.60)	0.8224
Index Hospitalization LOS (days)	1.0 (0.0, 2.0)	0.0 (0.0, 2.0)	0.1068	1.0 (0.0, 2.0)	0.0 (0.0, 2.0)	0.1797	1.0 (0.0, 2.0)	0.0 (0.0, 2.0)	0.4518
Came through ED (%, n)	43.24 (128)	56.76 (181)	0.8055	40.52 (94)	59.48 (138)	0.7440	53.13 (34)	46.88 (30)	1.000
Readmitted (%, n)	35.71 (5)	64.29 (9)	0.5211	-	-	-	35.71 (5)	64.29 (9)	0.1066
Time until Readmission (days)	10.43 (10.34)	16.0 (11.15)	0.2894	-	-	-	10.43 (10.34)	16.00 (11.15)	0.2894
Readmission Diagnosis (%, n)     Chest Pain    COPD	38.89 (7)0.00 (0)	61.11 (11)100.0 (2)	0.5211	-	-	-	38.89 (7)0.000 (0)	61.11 (11)100.00 (2)	0.5211
Cost of Readmission Hospitalization ($ USD)	1,854.26 (0.00, 4,071.65)	0.00 (0.00, 4,690.15)	0.5517	-	-	-	1,854.26(0.00, 4,071.65)	0.00(0.00, 4,690.15)	0.5517
Readmission Hospitalization LOS (days)	1.0 (0.0, 4.0)	1.0 (0.0, 2.0)	0.5921	-	-	-	1.0 (0.0, 4.0)	1.0 (0.0, 2.0)	0.5921





Table 12: Descriptive characteristics of the pre-period and post-period for the overall study population, with p-values provided for each breakdown of the overall, never readmitted, and readmitted populations for individuals diagnosed with COPD and bronchiectasis.
Variable	Overall Population	Never Readmitted Population	Readmitted Population
	Pre-Period(n=550)	Post-Period(n=499)	P-Value	Pre-Period(n=348)	Post-Period(n=288)	P-Value	Pre-Period(n=202)	Post-Period(n=211)	P-Value
Age (years)	66.0 (58.0, 72.0)	65.0 (58.0, 71.0)	0.0494*	66.0 (59.0, 73.0)	66.0 (58.0, 72.0)	0.5069	65.5 (58.0, 71.0)	62.0 (57.0, 69.0)	0.0334*
Gender (%, n)    Male    Female	51.87 (208)52.78 (342)	48.13 (193)47.22 (306)	0.7749	52.07 (113)56.09 (235)	47.93 (104)43.91 (184)	0.3352	51.63 (95)46.72 (107)	48.37 (89)53.28 (122)	0.3216
Race/Ethnicity (%, n)    White    African American    Hispanic/Latino    Other	51.40 (366)55.04 (142)55.17 (32)47.62 (10)	48.60 (346)44.96 (116)44.83 (26)52.38 (11)	0.7116	54.31 (233)58.55 (89)48.72 (19)43.75 (7)	45.69 (196)41.45 (63)51.28 (20)56.25 (9)	0.5175	47.00 (133)50.00 (53)68.42 (13)60.00 (3)	53.00 (53)50.00 (53)31.58 (6)40.00 (2)	0.2968
Type of Admission (%, n)    Observation    Inpatient	48.57 (17)52.56 (533)	51.43 (18)47.44 (481)	0.6419	38.46 (5)55.06 (343)	61.54 (8)44.94 (280)	0.2342	54.55 (12)48.59 (190)	45.45 (10)51.41 (201)	0.5868
Cost of Index Hospitalization ($ USD)	6,007.46 (4,751.69, 7,068.51)	5,293.60 (4,382.09, 6,251.32)	<0.0001*	5,938.27(4,745.49, 6,990.38)	5,413.08(4,473.94, 6,354.22)	0.0002*	6,175.46(4,782.33, 7,193.38)	5,181.53(4,138.03, 6,192.68)	<0.0001*
Index Hospitalization LOS (days)	3.0 (2.0, 5.0)	3.0 (2.0, 5.0)	0.9706	3.0 (2.0, 5.0)	3.0 (2.0, 5.0)	0.2378	3.0 (2.0, 6.0)	3.0 (2.0, 5.0)	0.1969
Came through ED (%, n)	52.73 (512)	47.27 (459)	0.4949	55.27 (325)	44.73 (263)	0.3249	48.83 (187)	51.17 (196)	0.9013
Readmitted (%, n)	56.58 (43)	43.42 (33)	0.4379	-	-	-	56.58 (43)	43.42 (33)	0.1196
Time until Readmission (days)	12.0 (4.0, 25.0)	13.5 (4.0, 21.0)	0.8593	-	-	-	12.0 (4.0, 25.0)	13.5 (4.0, 21.0)	0.8593
Readmission Diagnosis (%, n)     Chest Pain    COPD	100.0 (3)54.32 (44)	0.0 (0)43.59 (34)	0.2602	-	-	-	100.00 (3)56.41 (44)	0.00 (0)43.59 (34)	0.2602
Cost of Readmission Hospitalization ($ USD)	5,601.23 (0.00, 7,420.44)	5,054.91 (3,807.79, 6,212.36)	0.6338	-	-	-	5,601.23(0.00, 7,420.44)	5,045.91(3,807.79, 6,212.36)	0.6338
Readmission Hospitalization LOS (days)	3.0 (2.0, 5.0)	3.5 (2.0, 5.0)	0.7136	-	-	-	3.0 (2.0, 5.0)	3.5 (2.0, 5.0)	0.7136





Table 13: Significant variables for the index hospitalization cost models among individuals diagnosed with nonspecific chest pain.
Model	Total R2	Significant Associations	Standardized regression coefficient	P-value
Overall Nonspecific Chest Pain	0.270830	AgeLength of StayReport via ED	-32.27574.62535.69	0.0163<0.00010.0089
Never Readmitted Nonspecific Chest Pain	0.273083	Observation StatusAgeLength of StayReport via ED	-1,186.66-36.81318.521,334.47	0.00190.00200.00250.0142
Readmitted Nonspecific Chest Pain	0.321946	Length of Stay	870.98	<0.0001


Table 14: Significant variables for the index hospitalization cost models among individuals diagnosed with COPD and bronchiectasis.
Model	Total R2	Significant Associations	Standardized regression coefficient	P-value
Overall COPD and Bronchiectasis	0.188934	Observation StatusLength of Stay	-2,644.36545.66	0.0001<0.0001
Never Readmitted COPD and Bronchiectasis	0.247761	Length of Stay	793.18	<0.0001




Table 15: Significant variables for the index hospitalization length of stay, in days, models among individuals diagnosed with nonspecific chest pain.
Model	Total R2	Significant Associations	Standardized regression coefficient	P-value
Overall Nonspecific Chest Pain	0.370255	Observation StatusSum Comorbidities	-2.330.11	<0.00010.0175
Never Readmitted Nonspecific Chest Pain	0.478711	Observation Status	-2.32	<0.0001





Table 16: Significant variables for the index hospitalization length of stay, in days, models among individuals diagnosed with COPD and bronchiectasis.
Model	Total R2	Significant Associations	Standardized regression coefficient	P-value
Overall COPD and Bronchiectasis	0.058283	Observation StatusReport via ED	-3.71-0.98	<0.00010.0064
Never Readmitted COPD and Bronchiectasis	0.073043	Observation StatusFemaleAfrican AmericanReport via ED	-4.130.60-0.78-1.23	<0.00010.01000.00290.0042
Readmitted COPD and Bronchiectasis	0.074892	Observation Status	-3.75	<0.0001


Table 17: Significant variables for the probability of being admitted as an inpatient compared to receiving observation services for individuals diagnosed with nonspecific chest pain.
Model	Significant Associations	Standardized regression coefficient	Odds Ratio	P-value
Overall Nonspecific Chest Pain	After Time PeriodHispanic Sum Comorbidities	-0.2617-0.37830.1688	0.592 (0.366, 0.960)0.469 (0.239, 0.923)1.184 (1.063, 1.319)	0.03350.02840.0022
Never Readmitted Nonspecific Chest Pain	Sum Comorbidities	0.1662	1.181 (1.042, 1.338)	0.0090
Readmitted Nonspecific Chest Pain	None	-	-	-


Table 18: Significant variables for the probability of being admitted as an inpatient compared to receiving observation services for individuals diagnosed with COPD and bronchiectasis.
Model	Significant Associations	Standardized regression coefficient	Odds Ratio	P-value
Overall COPD and Bronchiectasis*	Report via ED	0.9141	6.223 (2.825, 13.708)	<0.0001
Never Readmitted COPD and Bronchiectasis*	HispanicReport via ED	-1.25291.6263	0.082 (0.018, 0.371)25.859 (6.815, 98.125)	0.0012<0.0001
Readmitted COPD and Bronchiectasis*	None	-	-	-
* Maximum likelihood estimate may not exist
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